^
Association details:
Biomarker:NOTCH2 mutation
Cancer:Diffuse Large B Cell Lymphoma
Regimen:R-CHOP (cyclophosphamide + doxorubicin hydrochloride + + Rituxan (rituximab) + vincristine)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma

Published date:
10/10/2021
Excerpt:
Here we analysed clinico-biological features in 373 DLBCL patients homogeneously treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP), in order to identify variables associated with early failure to treatment (EF)...Mutations in NOTCH2, gains in 5p15·33 (TERT), 12q13 (CDK2), 12q14·1 (CDK4) and 12q15 (MDM2) showed predictive importance for EF independently from R-IPI.
DOI:
10.1111/bjh.17858